Title:Navigating Cardiotoxicity in Cancer Treatment: Insights into Fluoropyrimidine-induced Cardiac Events
Volume: 22
Issue: 1
Author(s): Ashika Bhattarai*, Manodeep Chakraborty, Md. Hasnat Jahan Ali, Chetiz Sharma, Akanchya Rai, Rudra Acharya, Yuan Rai, Ananya Bhattacharjee and Nihar Ranjan Bhuyan
Affiliation:
- Department of Pharmacology, Himalayan Pharmacy Institute, Majhitar, Rangpo, East Sikkim, India
Keywords:
Fluropyrimidine, 5-FU, cardiotoxicity, coronary vasospasm, myocarditis, DPYD gene.
Abstract:
Introduction: Fluoropyrimidine (FP) is a key cancer treatment but often causes side
effects, notably cardiotoxicity. This cardiotoxicity can present as angina, arrhythmia, dyspnea,
and palpitations, requiring urgent cardiologist attention. The etiology, management, and frequency
of FP-induced cardiotoxicity are still unknown despite long-term use.
Objective: The article aims to provide an overview of the pathogenic occurrence, cardiac event
risk factor, possible underlying mechanism of FP-cardiotoxicity, diagnostics, and therapeutic
approach for the corrective management of this clinical condition.
Methods: Review was performed by searching extensively for various existing literature search
PubMed, Web of science and Scopus using suitable keywords to find articles that support our
review study.
Results and Discussion: FP induced cardiotoxicity results in morbidness and fatality in patient
undergoing the treatment. Thus, an effective management system must be standardized to effectively
treat and prevent this clinical condition.
Conclusion: The cardiotoxic event following 5-FU has been lesser-known clinical entity with
limited study on its pathophysiology and management. In the diagnosis procedure, each patient
undergoing FP treatment ought to have early symptom identity, risk categorization, and therapy
individualized based on benefit-risk ratio.
